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Abstract
Background: Oxidative stress is associated with increased cardiovascular morbidity and mortality
particularly in patients with end stage kidney disease. Although observational data from the general
population has shown dietary antioxidant intake is associated with reduced cardiovascular
morbidity and mortality, most clinical intervention trials have failed to support this relationship.
This may be a consequence of not using an effective antioxidant dose and/or not investigating
patients with elevated oxidative stress. The SPACE study, conducted in haemodialysis patients,
reported that 800 IU/day of alpha tocopherol significantly reduced cardiovascular disease
endpoints. A recent time course and dose response study conducted in hypercholesterolaemic
patients that found 1600 IU/day of alpha tocopherol was an optimal dose. There is no such dose
response data available for haemodialysis patients. Therefore the aim of this study is to investigate
the effect of different doses of oral alpha tocopherol on oxidative stress in haemodialysis patients
with elevated oxidative stress and the time taken to achieve this effect.
Methods: The study will consist of a time-course followed by a dose response study. In the time
course study 20 haemodialysis patients with elevated oxidative stress will take either 1600 IU/day
natural (RRR) alpha tocopherol for 20 weeks or placebo. Blood will be collected every two weeks
and analysed for a marker of oxidative stress (plasma F2-isoprostanes) and alpha tocopherol. The
optimum time period to significantly decrease plasma F2-isoprostanes will be determined from this
study. In the dose response study 60 patients will be randomised to receive either placebo, 100,
200, 400, 800 or 1600 IU/day of natural (RRR) alpha tocopherol for a time period determined from
the time course study. Blood will be collected at baseline and every two weeks and analysed for
plasma F2-isoprostanes and alpha tocopherol. It is hypothesised that doses ≥ 800 IU of vitamin E
will be required to significantly decrease plasma F2-isoprostanes.
Discussion:  This study will determine the time and dose required for alpha tocopherol to
significantly decrease oxidative stress in haemodialysis patients. Data will be used to plan a large
randomised controlled trial to assess the effects of alpha tocopherol on cardiovascular outcomes
in haemodialysis patients.
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Background
Oxidative stress is an important contributor to the devel-
opment of atherosclerosis and hence cardiovascular mor-
bidity and mortality [1]. Observational studies suggest
diets high in antioxidants such as alpha tocopherol may
be associated with decreased cardiovascular disease [2,3].
However, antioxidant intervention trials have failed to
demonstrate cardiovascular mortality benefits [4-11]. This
may be due to the type and dose of antioxidant selected
and the features of the populations studied. For example,
trials have not selected elevated oxidative stress as an
inclusion criteria therefore the study participants may not
have been the most likely to benefit.
Chronic kidney disease is associated with high levels of
oxidative stress, and treatment with haemodialysis can
further increase oxidative stress levels, which may contrib-
ute to high level of cardiovascular disease in these patients
[1,12]. These patients have a 10-20 times higher rate of
cardiovascular disease morbidity and mortality compared
to healthy people [13,14].
Alpha tocopherol is the main form of vitamin E and this
has been the most commonly studied dietary antioxidant
supplement in clinical trials. In one of the few trials to
demonstrate a beneficial cardiovascular affect, the Sec-
ondary Prevention with Antioxidants of Cardiovascular
disease in End stage renal disease (SPACE) study assessed
the effects of 800 IU of alpha tocopherol on cardiovascu-
lar outcomes in 196 haemodialysis patients [15]. In this
randomised controlled trial there was a significant reduc-
tion in cardiovascular disease endpoints and myocardial
infarction in treated patients. However, the design of this
study has been criticised, mainly for failure to measure
oxidative stress and vitamin E levels in most of the
patients [16-18] and because the study had a small sample
size with resultant wide confidence intervals for a broad
composite endpoint [19,20]. The authors responded but
only reported vitamin E and oxidative stress measures in
15 patients from each group [21].
A recognised weakness of many of the large vitamin E car-
diovascular trials is a lack of oxidative stress data assessing
whether the supplementation was pharmacologically
effective. In addition there has been evidence from meta-
analyses indicating potential safety concerns with higher
doses of alpha tocopherol [22].
Roberts et al (2007) conducted a time course and dose
determining study in hypercholesterolemic patients. They
reported that 1600 IU of alpha tocopherol was required
over 16 weeks to significantly reduce plasma F2-isopros-
tanes, a biomarker of oxidative stress [23]. No such data is
available for haemodialysis patients. Hence, this study has
been designed using this approach to establish a dose of
alpha tocopherol that will achieve a significant reduction
in oxidative stress, and to determine how long it would
need to be administered for, to achieve this effect. This
information will be used to plan a large, randomised con-
trolled trial to assess the effects of alpha tocopherol on
cardiovascular outcomes in haemodialysis patients.
Methods
Design and Setting
This investigation will involve two sequential compo-
nents, a time course, followed by a dose response study.
The studies will be conducted at the Renal Medicine
Department of the Royal Brisbane and Women's Hospital,
Brisbane, Australia, which services a population of
approximately 1.2 million people.
Ethical Considerations
The Royal Brisbane and Women's Hospital Research and
Ethics Committee approved the studies. The Ethics Com-
mittee will promptly receive all adverse event reports
along with a final report.
Eligibility
For both studies, inclusion criteria are; age > 18 and < 85
years, incident and prevalent dialysis patients, who are
undergoing regular three times per week, hospital based
haemodialysis and who have elevated oxidative stress.
Elevated oxidative stress will be defined as having total
plasma F2-isoprostane levels > 500 pg/mL. This is based
on a study that compared plasma F2-isoprostane levels in
chronic haemodialysis patients (1662 ± 289 pg/mL) with
matched healthy controls (396 ± 18 pg/mL) [24,25] and
the Roberts et al. (2007) study that defined elevated oxi-
dative stress as two standard deviations above the mean
[23].
Patients will be excluded if they are currently taking alpha
tocopherol or have been taking it in the previous three
months for at least one week, and if they are unable, or
unwilling to give informed consent. In addition, patients
who are participating in another investigational study, or
are within 30 days of completing an investigational study,
or patients who are taking warfarin, desimpramine, chlo-
rpromazine and chloroquine will also be ineligible.
Identification of Eligible Patients
Eligible patients will be screened from the haemodialysis
unit and will receive a copy of the patient information and
consent form. An investigator will then explain the study
during a clinical consultation. The patient will then be
asked to take the information and consent form away
with them and make a decision before their next haemo-
dialysis visit. If they agree to participate, they will sign the
consent form with an independent person signing as a
witness.BMC Nephrology 2009, 10:32 http://www.biomedcentral.com/1471-2369/10/32
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Randomization
An individual not associated with the trial will perform
the randomization for both studies using a computer gen-
erated random number system.
Time-course study
Twenty participants will be recruited for the time-course
study with ten randomly allocated to a treatment group
and ten to a placebo group. Both groups will be required
to take two capsules per day (one in the morning and one
at night) each containing either a placebo or 800 IU of
natural (RRR) alpha tocopherol (total 1600 IU/day) for
20 weeks.
Dose-response study
Following the time course study, sixty participants will be
recruited for the dose-response study with placebo, 100
IU/day, 200 IU/day, 400 IU/day, 800 IU/day and 1600
IU/day natural (RRR) alpha tocopherol groups each con-
sisting of ten people. If patients from the time course
study agree to participate in the dose-response study they
will undergo a 12-week period (wash out) where they will
not be consuming alpha tocopherol. Dose-response study
participants will be required to take two capsules per day
(one in the morning and one at night) containing either a
placebo or alpha tocopherol, to provide the respective IU/
day doses.
The placebo will contain the emulsifying agent (wheat-
germ oil) used in the alpha tocopherol supplement. Cog-
nis Nutrition & Health Pty Ltd, Sydney, Australia, will
supply all capsules.
Blinding and concealment
All vitamin E and placebo capsules will be identical. The
allocation will be provided coded to the person who dis-
penses the medication thus ensuring the dispenser and
patient are blinded to the allocation.
Adverse event monitoring
A medical co-investigator will assess whether reported
adverse events are related to the study medication and will
also assess all signs, symptoms and complaints. All
adverse events, regardless of relationship to the study, will
be recorded and will include; the specific condition or
event and direction of change, whether the condition is
pre-existing, the dates and times of the occurrence, the
severity and significance to study, the action taken and the
outcome.
Serious adverse events recorded will include death, in-
patient hospitalisation, persistent or significant disability
or incapacity, cancer, or be life threatening. Additionally,
important medical events that may not result in the above
stated outcomes but may require medical or surgical inter-
vention will also be reported.
Primary Objectives and Outcome Measures
The first primary objective is to determine the time point
when oxidative stress is significantly reduced in haemodi-
alysis patients taking 1600 IU/day of alpha tocopherol.
Based on the Roberts et al. (2007) study in hypercholeste-
rolemic patients, it is hypothesised that this will occur at
16-weeks [23].
Using this information, the second primary objective is to
determine the optimal dose of alpha tocopherol required
to reduce oxidative stress in patients undergoing haemo-
dialysis. Based on the SPACE trial, it is hypothesised that
≥ 800 IU of alpha tocopherol will be required to signifi-
cantly reduce oxidative stress [15].
Secondary Objectives and Outcome Measures
For both studies, secondary objectives will be to deter-
mine the effects of alpha tocopherol on additional meas-
ures of oxidative stress and antioxidant status. The
additional measures will be plasma protein carbonyls,
malondialdehyde and antioxidant enzyme activities of
superoxide dismutase, glutathione peroxidase and cata-
lase.
Visit One (establishment of oxidative stress status)
After obtaining written, signed and witnessed informed
consent patients will have blood taken from the dialysis
line, at the start of dialysis, to measure total plasma F2-iso-
prostanes to assess their eligibility (> 500 pg/ml) to
progress to the next phase of the study.
Visit two
Once randomized, patients will be booked into a clinic
appointment for baseline trial measures. This will occur
on a mid-week dialysis day. At the first trial visit, addi-
tional data will be obtained from the medical records
(medical history, medications) and measures of height,
weight and blood pressure will be recorded. Additional
blood will be collected pre-dialysis for routine blood
chemistry and for measures of plasma F2-isoprostanes and
alpha tocopherol.
Time course study
Participants recruited into the time-course study will be
required to consume 1600 IU of alpha tocopherol orally
each day for 20 weeks or an identical placebo. Blood sam-
ples of 8 mL will be taken once every fortnight from the
dialysis line, at the start of dialysis, during a normal mid-
week dialysis visit and analysed for plasma F2-isopros-
tanes and alpha tocopherol.
Dose-response study
Participants recruited for the dose-response study will be
allocated after randomisation to consume either a pla-
cebo, 100 IU, 200 IU 400 IU, 800 IU or 1600 IU of alpha
tocopherol orally each day for the duration determined byBMC Nephrology 2009, 10:32 http://www.biomedcentral.com/1471-2369/10/32
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the time-course study. Blood samples of 8 mL will be
taken at the completion of the time period from the dial-
ysis line, at the start of dialysis, during their normal mid-
week dialysis visit and analysed for plasma F2-isopros-
tanes and alpha tocopherol
Adherence to Therapy
Patients will be required to return the container each
month with unused capsules inside. Adherence to therapy
will be assessed by duplicate table counts of the remaining
capsules conducted independently by two study investiga-
tors.
Withdrawal from Study
Patients will be withdrawn from the study at their request,
without prejudice, as documented and explained at the
time of consenting. Patients who withdraw will be invited
to consent to follow-up testing for the remainder of the
trial to enable an intention to treat data analysis.
Blood collection, separation and storage
EDTA blood (approx. 8 mL) will be collected from the
sample line shortly after the patient has commenced dial-
ysis. If there is considerable time (> 10 mins) between
blood collection and separation then the blood sample
will be placed on ice. Centrifugation will be at 600 × g for
10 mins with plasma aliquots then stored at -80°C.
F2-isoprostanes
Total isoprostanes (8-iso-PGF2α) will be extracted from
plasma according to a modified method of Taylor and col-
leagues [26]. Samples from the freezer will be thawed on
ice then diluted with distilled water and spiked with an
internal standard; 8-iso-PGF2α-d4  (Cayman chemical,
Michigan, USA) before methanolic NaOH solution is
added. The solution will be vortexed, caped and placed in
a water bath at 37°C for 60 min. This is followed by fur-
ther dilution with distilled water and then acidification to
pH 3 with hydrochloric acid before being extracted with
hexane. Following gentle rotation and centrifugation at
3000 × g, hexane extracts will be removed and discarded.
The aqueous layer will then be extracted twice with ethyl
acetate, with extracts pooled and dried under nitrogen.
Once dry, the samples will be reconstituted with ace-
tonitrile, vortexed and transferred into 300 μL glass inserts
and dried ready for derivatisation. The derivatization
method will be based on that used by Mori and colleagues
[27]. To the dried extract, pentafluorobenzylbromide and
20 μL diisopropylethylamine will be added and incubated
at room temperature for 30 min. Following incubation,
samples will be further dried under nitrogen to give the F2-
isoprostane pentafluorobenzyl ester. Samples will then be
treated with pyridine, bis(trimethylsilyl)trifluoroaceta-
mide and trimethylchlorosilane and incubated at 45°C
for 20 min to yield the trimethylsilylethers. After incuba-
tion, hexane will be added to each sample, mixed and
placed in the auto sampler. Samples will then be analyzed
using a Varian 320 MS/MS with a Varian 450 gas chroma-
tograph using Varian MS Workstation - system control
software version 6.9.1 (Varian, Australia). Using a 10 μL
Hamilton syringe with 1.2 μL of sample injected for each
analysis. The injector will operate at 250°C with a Varian
FactorFour Capillary Column - VF - 5 ms 30 m × 0.25 mm
ID DF = 0.25 using helium as the carrier gas at a flow rate
of 1.0 ml·min-1 with pressure maintained at 13.9 psi. The
column oven will start at 160°C held for one minute then
increase to 300°C over 7 min then holding for 10 min for
an overall run time of 18 min with the peaks eluting
around 10.3 min. Running in negative chemical ioniza-
tion mode the reagent gas will be methane with an ion
source pressure of 7.00 Torr and argon as the collision gas
at a pressure of 2.00 mTorr. The mass size of our com-
pounds is expected to be 569 and 573 for isoprostanes
and the internal standard, respectively.
Alpha tocopherol
Plasma alpha tocopherol levels will analysed using a
modified HPLC method from Katsandinis et al. [28].
Plasma aliquots will be thawed on ice and mixed with eth-
anol/BHT and vortexed. Hexane will then be added and
samples gently mixed for 10 mins before being centri-
fuged at 4,000 × g for 10 mins. The hexane layer will be
removed, dried and reconstituted with mobile phase con-
taining hexane and isopropanol. Vitamin E concentra-
tions will be measured at 295 nm using HPLC (Shimazu)
with a LiChrospher C18 column (250 × 4 mm, 5 μm, 1
ml/min flow rate, 9 MPa backpressure).
Sample Size Calculation
The primary outcome measure for both studies will be the
total plasma F2-isoprostane levels. For both studies, we
will assume that the initial plasma F2-isoprostane levels
will be 1600 ± 300 pg/mL. This is based on the inclusion
criteria requiring patients to have plasma F2-isoprostane
levels > 500 pg/mL, and also data showing plasma F2-iso-
prostane levels in haemodialysis patients were 1662 ± 289
pg/mL [24,25]. A decrease in plasma F2-isoprostane levels
to 50% (800 pg/mL) of the initial values will be regarded
as significant. To our knowledge, there is little data to sup-
port this assumption as no studies have assessed the rela-
tionships between plasma F2 isoprostanes and long-term
health outcomes. Data from the Roberts et al. (2007)
study found an approximately 50% reduction in plasma
F2-isoprostane levels after 16 weeks vitamin E treatment in
hypercholesterolemic patients [23]. With these assump-
tions, accepting their limitations and using a change vari-
ance of 350 pg/mL, with alpha = 0.05, beta = (1-0.1 = 0.9)
we require five subjects per group. Assuming that five sub-
jects per group will withdraw, die or receive a kidney
transplant during the trial we will recruit ten subjects per
group for both studies.BMC Nephrology 2009, 10:32 http://www.biomedcentral.com/1471-2369/10/32
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Statistical Analyses
The analysis of both the time-course and dose-ranging
study will focus on analysing the changes in the levels of
plasma F2-isoprostanes and alpha tocopherol, which
occur during the intervention. The time-course study will
use general linear modelling to analyse the levels of
plasma F2-isoprostanes at bi-weekly intervals and levels of
alpha tocopherol will be compared at baseline and week
20. In the dose-ranging study we will use general linear
modelling to compare the changes in plasma F2-isopros-
tane levels between the intervention and placebo group at
baseline and at the completion of the study. All statistical
analyses will be performed using STATA statistical soft-
ware (STATA 10; Statistical data analysis; Stata Corp; Col-
lege Station; Texas, USA).
Discussion
Despite observational studies suggesting alpha tocopherol
may protect from cardiovascular disease, most interven-
tional studies have failed to support this contention.
There may be many reasons for this discrepancy including
the fact many patients treated in such studies may not
have had elevated levels of oxidative stress. In addition,
the administered alpha tocopherol may not have lowered
oxidative stress. This time course and dose response study
of alpha tocopherol in haemodialysis patients will pro-
vide data to support further large randomised controlled
trials in this area.
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